Carlotti Françoise, Zaldumbide Arnaud, Ellenbroek Johanne H, Spijker H Siebe, Hoeben Rob C, de Koning Eelco J
Department of Nephrology, Leiden University Medical Center, Postal Zone C3-P, P.O. Box 9600, 2300 RC Leiden, The Netherlands.
J Transplant. 2011;2011:892453. doi: 10.1155/2011/892453. Epub 2011 Oct 5.
β-cell replacement by allogeneic islet transplantation is a promising approach for patients with type 1 diabetes, but the shortage of organ donors requires new sources of β cells. Islet regeneration in vivo and generation of β-cells ex vivo followed by transplantation represent attractive therapeutic alternatives to restore the β-cell mass. In this paper, we discuss different postnatal cell types that have been envisaged as potential sources for future β-cell replacement therapy. The ultimate goal being translation to the clinic, a particular attention is given to the discrepancies between findings from studies performed in rodents (both ex vivo on primary cells and in vivo on animal models), when compared with clinical data and studies performed on human cells.
同种异体胰岛移植进行β细胞替代对于1型糖尿病患者而言是一种很有前景的方法，但器官供体短缺需要新的β细胞来源。体内胰岛再生以及体外生成β细胞后进行移植是恢复β细胞数量的有吸引力的治疗选择。在本文中，我们讨论了不同的出生后细胞类型，这些细胞类型被设想为未来β细胞替代疗法的潜在来源。最终目标是转化应用于临床，因此特别关注与临床数据以及对人类细胞进行的研究相比，在啮齿动物中进行的研究（包括原代细胞的体外研究和动物模型的体内研究）结果之间的差异。
